RGEN logo

REPLIGEN CORP

RGENNASDAQ
πŸ† #821 by market capEarnings Oct 26 Β· PreUS Equity
$164.77β–² $1.61 (+0.98%)
πŸŒ… Pre-market$164.80β–² 0.02%Regular close Β· extended-hours price shown
1hβ€”
24hβ–² 1.0%
7dβ–² 3.8%
14dβ–² 16.5%
30dβ–² 13.8%
1yβ–² 35.7%
🏦Market Cap
$9.30B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+16.5%
Healthy
πŸ“ŠGross Margin
53.8%
Healthy
πŸ’΅FCF Margin
14.0%
Healthy
βš–οΈP/S Ratio
11.7x
Elevated
Otter Score
43
Weak

Trading Snapshot

Day Range
$163.01 – $165.85
52-Week Range
$100.99 – $175.77
Volume
$1.64B
Avg Volume
$1.88B
Shares Outstanding
56.4M
Next Earnings
Sep 15, 2026

Fundamentals Snapshot

Annual Revenue
$738M
Last Q Revenue
$204M
P/E Ratio
220.8
P/S Ratio
11.7x
EPS (TTM)
$0.73
Dividend Yield
β€”

Why Investors Own RGEN

  • βœ“High-growth profile β€” revenue up +36.2% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 63% gross margin and 8% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$738Mβ–² +32.8% YoY
Gross Margin (TTM)
63.4%β–² +3.3% YoY
Operating Income (TTM)
$148Mβ–² +32.8% YoY
Free Cash Flow (TTM)
$60Mβ–² +32.8% YoY

About REPLIGEN CORP

Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
43/100

Analyst Price Target

β“˜
Average Target
$173.30
β–² +5.2% Upside
High Target$187.83
Low Target$137.80
Based on 38 analysts

Latest News & Updates